How to apply the personalized medicine in obesity-associated asthma?

Tiotiu, Angélica; Labor, Marina; Nedeva, Denislava; Novakova, Silviya; Oğuzülgen, I. Kıvılcım; Mihăicuță, Ștefan; Braido, Fulvio

doi:10.1080/17476348.2020.1780123

Cited by 5 publications

(3 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Obesity is associated with exacerbation of the inflammatory and immune response in asthma patients, depending on an increased synthesis of leptin, IL-6, and TNF-α. In addition, visceral fat accumulation may decrease lung volumes by reducing chest wall compliance [ 35 ].…”

Section: Clinical Overlap Between Asthma and Pcosmentioning

confidence: 99%

The “Asthma-Polycystic Ovary Overlap Syndrome” and the Therapeutic Role of Myo-Inositol

Guarnieri

Iervolino²,

Cavallone³

et al. 2023

IJMS

View full text Add to dashboard Cite

Asthma is a heterogeneous inflammatory disease characterized by abnormalities in immune response. Due to the inherent complexity of the disease and the presence of comorbidities, asthma control is often difficult to obtain. In asthmatic patients, an increased prevalence of irregular menstrual cycles, infertility, obesity, and insulin resistance has been reported. Given that these conditions are also common in patients with polycystic ovary syndrome (PCOS), we propose the definition of “asthma-PCOS overlap syndrome” to indicate a medical condition which shares characteristics of both diseases. The aim of this review is to analyze the links between asthma and PCOS and evaluate the therapeutic role of myo-inositol, a natural compound currently utilized in patients with PCOS, in the management of asthma patients.

show abstract

Section: Clinical Overlap Between Asthma and Pcosmentioning

confidence: 99%

The “Asthma-Polycystic Ovary Overlap Syndrome” and the Therapeutic Role of Myo-Inositol

Guarnieri

Iervolino²,

Cavallone³

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…В одному проспективному дослідженні, пацієнти, які отримували омалізумаб (anti-IgE-антитіла), мали поліпшення контролю захворювання та функції легень, а також зменшення кількості загострень та використання рятувальних ліків протягом 12-місячного періоду дослідження. Однак ці дані не є однозначними, оскільки інше дослідження показує зниження ефективності омалізумабу у пацієнтів з ожирінням порівняно з хворими без ожиріння [46]. В свою чергу бенралізумаб (anti-IL5) при БА з ожирінням, показав, що пацієнти з індексом маси тіла (ІМТ) більше 35 кг/м 2 з меншою ймовірністю знижували частоту загострень порівняно з пацієнтами з ІМТ менше 35 кг/м 2 .…”

Section: лікувально-реабілітаційні програми у хворих на ба з ожиріннямunclassified

“…Таким чином, сьогодні особливість терапії БА з ожирінням полягає в націлюванні на основні аберрантні процеси, такі як вирішення проблеми стероїдної резистентності, мікробіом, метаболізм та пошук підходів до зниження маси тіла. У цих пацієнтів саме лікування ожиріння має бути першочерговим лікуванням [46].…”

Section: лікувально-реабілітаційні програми у хворих на ба з ожиріннямunclassified

Current Views on the Role of the Pro-Inflammatory Cytokine IL-26 in the Development and Clinical Course of Bronchial Asthma Associated with Obesity and Treatment Strategy

Avramenko,

Kaidashev

2023

View full text Add to dashboard Cite

Abstract. In Ukraine and the world, the incidence of bronchial asthma (BA) and obesity among children and adults is simultaneously increasing, which is a serious problem of public health and health care management. Modern research links both diseases. The aim: To analyze the pathogenetic relationship between BA and obesity, to formulate a clinical understanding, the pathophysiology of asthma and obesity phenotypes, the impact and effectiveness of strategies for the treatment of obesity and obesity in combination with BA. Materials and methods. Analytical review of scientific publications by topic was performed using the databases of scientific libraries, search engines Google Scholar, Pub Med, Science Direct, etc. Results. To date, various hypotheses have been proposed to explain the association between obesity and asthma, such as a general genetic predisposition, impaired body development, altered respiratory mechanics, the presence of a systemic inflammatory process, and an increased prevalence of comorbidities in this cohort of patients. Patients with obesity and BA have more symptoms, a more severe course of BA, insufficient effectiveness of standard treatment, progressive deterioration of the quality of life. Despite more than a decade of research into the association between these diseases, the exact mechanisms underlying the interaction between obesity and asthma remain largely unclear and require further study. Understanding the mechanism of the association between obesity and asthma may lead to the development of new effective therapeutic strategies for the treatment of this sensitive population. Conclusions. The prevalence of the disease, the economic costs of treatment and its ineffectiveness require further scientific research in this direction. It is necessary to determine the role of new biomarkers, including IL-26, in the development and clinical course of BA in combination with obesity and to improve the effectiveness of treatment of such patients.

show abstract

Asthme de l’obèse ou l’importance des interventions non pharmacologiques

Guilleminault

2021

La Presse Médicale Formation

View full text Add to dashboard Cite

How to apply the personalized medicine in obesity-associated asthma?

Cited by 5 publications

References 110 publications

The “Asthma-Polycystic Ovary Overlap Syndrome” and the Therapeutic Role of Myo-Inositol

The “Asthma-Polycystic Ovary Overlap Syndrome” and the Therapeutic Role of Myo-Inositol

Current Views on the Role of the Pro-Inflammatory Cytokine IL-26 in the Development and Clinical Course of Bronchial Asthma Associated with Obesity and Treatment Strategy

Asthme de l’obèse ou l’importance des interventions non pharmacologiques

Contact Info

Product

Resources

About